

Note: This document has been translated from a part of the Japanese original for reference purposes only. In the event of any discrepancy between this translated document and the Japanese original, the original shall prevail. The Company assumes no responsibility for this translation or for direct, indirect or any other forms of damages arising from the translation.

(Securities Code 4694)

June 5, 2026

(Start of measures for electronic provision: June 4, 2026)

To Shareholders with Voting Rights:

Kensuke Kondo
President and Representative Director
BML, Inc.
5-21-3 Sendagaya, Shibuya-ku, Tokyo

NOTICE OF THE 71ST ANNUAL GENERAL MEETING OF SHAREHOLDERS

We would like to express our appreciation for your continued support and patronage.

We are pleased to inform you that the 71st Annual General Meeting of Shareholders of BML, Inc. (the “Company”) will be held for the purposes as described below.

In convening this Annual General Meeting of Shareholders, the Company has taken measures to provide information electronically, and posted matters subject to the electronic provision measures on the following website.

The Company’s website:

<https://www.bml.co.jp/eng/ir/index.html>

In addition to the website above, we post them on the following website.

Tokyo Stock Exchange’s website:

<https://www2.jpx.co.jp/tseHpFront/JJK020010Action.do>

Please access the Tokyo Stock Exchange (TSE) website above and enter our company name or securities code (4694). Then, click “Basic Information” and “Documents for Public Inspection/PR Information” to search “Notice of General Shareholders Meeting/Informational Materials for a General Shareholders Meeting” under “Filed information available for public inspection. ”

If you are unable to attend the meeting in person, you can exercise your voting rights in advance in writing or via the Internet. Please review the Reference Documents for the General Meeting of Shareholders included in the matters subject to the electronic provision measures, and exercise your voting rights by no later than 5:30 p.m. on Thursday, June 25, 2026, Japan time.

- 1. Date and Time:** Friday, June 26, 2026 at 10:00 a.m., Japan time
2. Place: Nishiki, South Tower 4F, Keio Plaza Hotel
2-2-1 Nishi-Shinjuku, Shinjuku-ku, Tokyo, Japan

3. Meeting Agenda:

- Matters to be reported:**
1. Business Report, Consolidated Financial Statements for the Company's 71st Fiscal Year (April 1, 2025–March 31, 2026) and results of audits of the Consolidated Financial Statements by the Accounting Auditor and the Audit and Supervisory Committee
 2. Non-consolidated Financial Statements for the Company's 71st Fiscal Year (April 1, 2025–March 31, 2026)

Proposals to be resolved:

- Proposal 1:** Distribution of Surplus
Proposal 2: Election of 9 Directors (Excluding Directors Who Are Audit and Supervisory Committee Members)
Proposal 3: Election of 1 Substitute Director Who Is an Audit and Supervisory Committee Member

- When attending the meeting, please submit the enclosed Voting Rights Exercise Form at the reception desk.
- You can exercise your voting rights by mail or electronic media (via the Internet, etc.). By following “Guidance for Exercise of Voting Rights” on pages 5 and 6 of the Japanese version of this document, please exercise your voting rights by no later than 5:30 p.m. on Thursday, June 25, 2026, Japan time.
- In the event that voting rights are exercised multiple times via the Internet, etc., only the final vote submitted shall be considered valid.
- In the event that voting rights are exercised in duplicate by mailing the Voting Rights Exercise Form and via the Internet, etc., the voting rights exercised through the Internet, etc. shall be considered valid.
- If revisions are made to the matters subject to the electronic provision measures, the details of the revisions will be posted on the aforementioned websites.
- Of the matters subject to the electronic provision measures, the following materials are not included in the notice of this annual general meeting of shareholders in accordance with relevant laws and regulations and the provisions of Article 16, Paragraph 2 of the Company's Articles of Incorporation. Accordingly, the documents are parts of the documents the Audit and Supervisory Committee Members and Accounting Auditor audited when they prepared their respective audit reports.
 - “System for ensuring the properness of the operations”
 - “Overview of the system for ensuring the properness of the operations”
 - “Consolidated statements of changes in shareholders' equity”
 - “Notes to consolidated financial statements”
 - “Non-consolidated statement of changes in equity”
 - “Notes to non-consolidated financial statements”

Reference Documents for the General Meeting of Shareholders

Proposals and References

Proposal 1: Distribution of Surplus

The Company recognizes the appropriate return of profits to shareholders as one of its important management priorities and intends to strive for improvement of the dividend level commensurate with the consolidated financial results based on the basic policy of maintaining continuous, stable dividends.

The year-end dividend of surplus for this year shall be paid as follows, based on such basic policy.

Items Related to the Year-end Dividend

(1) Type of dividend property
Cash

(2) Items related to the allocation of dividend property and the total amount
65.0 yen per common share of the Company
Total amount: 2,436,433,935 yen

The annual dividend for this year will be 125.0 yen per share including the interim dividend of 60.0 yen per share which has been already paid.


(3) Date the distribution of surplus comes into effect
June 29, 2026


Proposal 2: Election of 9 Directors (Excluding Directors Who Are Audit and Supervisory Committee Members)


The terms of office of all 9 Directors (excluding Directors who are Audit and Supervisory Committee Members; the same applies hereinafter in this proposal) will expire at the conclusion of this General Meeting of Shareholders. Accordingly, the Company proposes to elect 9 Directors.

The candidates for Directors are as follows. Matters on the candidates for Directors are provided on pages 5 to 13.


No.	Name	Positions and responsibilities in the Company	Attendance at meetings of the Board of Directors
1	Kensuke Kondo (Reappointment)	President and Representative Director	100% 16 out of 16 times
2	Norihisa Takebe (Reappointment)	Representative Director; Senior Managing Executive Officer; Division Manager, Planning Division; in charge of Marketing Division	100% 16 out of 16 times
3	Kenji Shibata (Reappointment)	Director; Managing Executive Officer; Division Manager, BML Testing Division, Department Manager, Third General Laboratory Testing Department; Department Manager, Reagent Department	100% 16 out of 16 times
4	Hideaki Osawa (Reappointment)	Director; Executive Officer; Division Manager, Marketing Division; Department Manager, Proposal Marketing Department; Department Manager, Clinical Trial Marketing Department	100% 16 out of 16 times
5	Yuji Yamashita (Reappointment)	Director; Executive Officer; Division Manager, System Division	100% 16 out of 16 times
6	Masami Kondo (New appointment)	Managing Executive Officer; Division Manager, In-Hospital Testing Division; Department Manager, Second In-Hospital Testing Department; Deputy Head in charge of Marketing Division; Deputy Head in charge of BML Testing Division	-
7	Shigeru Osawa (Reappointment) (Outside) (Independent)	Director	100% 16 out of 16 times
8	Reiko Matsuzawa (Reappointment) (Outside) (Independent)	Director	100% 12 out of 12 times
9	Toyohiko Kagawa (New appointment) (Outside) (Independent)		-


No.	Name (Date of birth)	Past experience, positions and responsibilities in the Company	Number of shares of the Company held
1	 <p data-bbox="181 680 410 801">Kensuke Kondo (September 18, 1966) (Reappointment)</p>	<p data-bbox="427 300 1209 488"> May 1994 Obtained a medical license June 1994 Director of the Company June 2004 Executive Officer in charge of medical science June 2006 Director; Executive Officer in charge of medical science January 2014 President and Representative Director To present </p> <p data-bbox="427 495 1289 745"> [Significant concurrent positions] • Chairman and Representative Director, Daiichi Kishimoto Clinical Laboratories, Inc. • Chairman and Representative Director, Okayama Medical Laboratory Company • Chairman and Representative Director, PCL Japan, Inc. • Chairman and Representative Director, Japan Clinical Service, Inc. • Chairman and Representative Director, OPL, Inc. • President and Representative Director, BML Planning, Inc. • President and Representative Director, Estate Kogyo Limited Company </p> <p data-bbox="427 779 1273 1019"> (Reasons for nomination) Dr. Kensuke Kondo has abundant experience and deep insight on overall medical industry from his experience as a doctor. Since assuming position as Representative Director in January 2014, he has been leading the Group's management. Based on his wealth of achievement from his excellent leadership, the Company has judged that he is personnel necessary to increase future corporate value of the Group, and therefore nominates him again as a candidate for Director. </p>	3,534,263

No.	Name (Date of birth)	Past experience, positions and responsibilities in the Company	Number of shares of the Company held
2	 <p data-bbox="209 853 384 965">Norihisa Takebe (April 28, 1962)</p> <p data-bbox="209 943 384 976">(Reappointment)</p>	<p data-bbox="432 271 1283 327">April 2015 Joined the Company; Department Manager, Sales Management Department; Department Manager, Finance Department</p> <p data-bbox="432 327 1283 439">April 2016 Executive Officer; Department Manager, Corporate Planning Department; Department Manager, Associated Business Department; Department Manager, Sales Management Department; Department Manager, Finance Department</p> <p data-bbox="432 439 1283 584">June 2016 Director; Executive Officer; Deputy Division Manager, Planning Division; Department Manager, Corporate Planning Department; Department Manager, Associated Business Department; Department Manager, Sales Management Department; Department Manager, Finance Department</p> <p data-bbox="432 584 1283 696">June 2021 Director; Managing Executive Officer; Division Manager, Planning Division; Department Manager, Corporate Planning Department; Department Manager, Sales Management Department; Department Manager, Finance Department</p> <p data-bbox="432 696 1283 875">June 2022 Director; Senior Managing Executive Officer; Division Manager, Planning Division; Department Manager, Corporate Planning Department; Department Manager, Sales Management Department; Department Manager, Finance Department; Department Manager, Associated Business Department</p> <p data-bbox="432 875 1283 965">June 2023 Representative Director; Senior Managing Executive Officer; Division Manager, Planning Division; Department Manager, Group Planning Department</p> <p data-bbox="432 965 1283 1077">May 2024 Representative Director; Senior Managing Executive Officer; Division Manager, Planning Division; in charge of Marketing Division</p> <p data-bbox="632 1055 743 1088">To present</p> <p data-bbox="421 1088 759 1122">[Significant concurrent positions]</p> <ul data-bbox="421 1122 1222 1178" style="list-style-type: none"> • Representative Director and President, Q-syu Open Laboratories, Inc. (to be assumed in June 2026) <p data-bbox="421 1178 687 1211">(Reasons for nomination)</p> <p data-bbox="421 1211 1246 1424">Mr. Norihisa Takebe has knowledge and experience of financial business. Since joining the Company, he has involved mainly in finance, corporate planning and group company management divisions and has abundant experience and deep insight on the Company's overall business. By utilizing such achievements, expertise as well as insights on management, the Company has judged that he is personnel necessary to increase the future corporate value of the Group, and therefore nominates him again as a candidate for Director.</p>	11,938

No.	Name (Date of birth)	Past experience, positions and responsibilities in the Company	Number of shares of the Company held
3	 <p data-bbox="188 808 400 927">Kenji Shibata (December 20, 1959) (Reappointment)</p>	<p data-bbox="427 271 1287 1126"> April 1984 Joined the Company April 2014 Department Manager, Inspection Department I June 2017 Director, Morioka Medical Laboratories, Inc. June 2018 Executive Officer; Division Manager, Planning Division of the Company June 2022 Director; Executive Officer; Division Manager, BML Testing Division; Department Manager, Testing Planning Department, Department Manager, First General Laboratory Testing Department; Department Manager, Second General Laboratory Testing Department; Department Manager, Fourth General Laboratory Testing Department April 2023 Director; Executive Officer; Division Manager, BML Testing Division; Department Manager, Testing Planning Department, Department Manager, Second General Laboratory Testing Department; Department Manager, Fourth General Laboratory Testing Department April 2025 Director; Executive Officer; Division Manager, BML Testing Division; Department Manager, Fourth General Laboratory Testing Department June 2025 Director, Managing Executive Officer, Division Manager, BML Testing Division; Department Manager, Third General Laboratory Testing Department; Department Manager, Fourth General Laboratory Testing Department; Department Manager, Reagent Department April 2026 Director, Managing Executive Officer, Division Manager, BML Testing Division; Department Manager, Third General Laboratory Testing Department; Department Manager, Reagent Department To present </p> <p data-bbox="427 1160 1287 1400"> (Reasons for nomination) Since joining the Company, Mr. Kenji Shibata has been involved mainly in testing division and has abundant experience and deep insight on the Company's overall business. By utilizing such achievements, expertise as well as insights on strategy planning, the Company has judged that he is personnel necessary to increase the future corporate value of the Group, and therefore nominates him again as a candidate for Director. </p>	9,244

No.	Name (Date of birth)	Past experience, positions and responsibilities in the Company	Number of shares of the Company held
4	 <p data-bbox="188 763 400 887">Hideaki Osawa (February 13, 1964) (Reappointment)</p>	<p data-bbox="427 271 1283 763"> September 1986 Joined the Company July 2008 Department Manager, Kinki Marketing Department April 2016 Executive Officer; Deputy Division Manager, Marketing Management Division; Sector Manager, Tokyo Branch Office June 2019 Director; Executive Officer; Deputy Division Manager, Marketing Management Division; Department Manager, Proposal Planning Department April 2021 Director; Executive Officer; Division Manager, Marketing Management Division; Division Manager, Marketing Promotion Division; Department Manager, Proposal Marketing Department; Department Manager, Clinical Trial Marketing Department June 2023 Director; Executive Officer; Division Manager, Marketing Division; Department Manager, Proposal Marketing Department; Department Manager, Clinical Trial Marketing Department To present </p> <p data-bbox="427 770 1283 860"> [Significant concurrent positions] • President and Representative Director, Daiichi Kishimoto Clinical Laboratories, Inc. (to be assumed in June 2026) </p> <p data-bbox="427 891 1283 1128"> (Reasons for nomination) Since joining the Company, Mr. Hideaki Osawa has involved mainly in marketing division and also served as Representative Director at a collection and delivery- related subsidiary, and he has abundant experience and deep insight on the Company's overall business. By utilizing such achievements, expertise as well as insights on management, the Company has judged that he is personnel necessary to increase the future corporate value of the Group, and therefore nominates him again as a candidate for Director. </p>	8,034

No.	Name (Date of birth)	Past experience, positions and responsibilities in the Company	Number of shares of the Company held
5	 <p data-bbox="209 618 384 741">Yuji Yamashita (August 6, 1965) (Reappointment)</p>	<p data-bbox="432 277 1283 506">November 1988 Joined the Company April 2020 Department Manager, Laboratory Information System Department July 2020 Executive Officer; Deputy Division Manager, System Division; Department Manager, Core System Department June 2022 Director; Executive Officer; Division Manager, System Division To present</p> <p data-bbox="432 539 1283 779">(Reasons for nomination) Since joining the Company, Mr. Yuji Yamashita has been involved mainly in the systems division and has abundant experience and deep insight on the Company's overall business. By utilizing such achievements, expertise as well as insights on strategy planning, the Company has judged that he is personnel necessary to increase the future corporate value of the Group, and therefore nominates him again as a candidate for Director.</p>	6,286

No.	Name (Date of birth)	Past experience, positions and responsibilities in the Company	Number of shares of the Company held
6	 <p data-bbox="193 748 400 869">Masami Kondo (May 20, 1965) (New appointment)</p>	<p data-bbox="432 271 1283 1010"> April 1988 Joined the Company April 2016 Department Manager, Proposal Planning Department June 2017 Executive Officer; Deputy Division Manager, Marketing Management Division; Department Manager, Proposal Planning Department; Department Manager, Preventive Medicine Marketing Department January 2021 Executive Officer; Division Manager, In-Hospital Testing Division; Department Manager, First In-Hospital Testing Department; Department Manager, Second In-Hospital Testing Department June 2022 Managing Executive Officer; Division Manager, In-Hospital Testing Division; Department Manager, First In-Hospital Testing Department; Department Manager, Second In-Hospital Testing Department May 2024 Managing Executive Officer; Division Manager, In-Hospital Testing Division; Department Manager, In-Hospital Testing Management Department; Department Manager, First In-Hospital Testing Department; Department Manager, Second In-Hospital Testing Department; and Deputy Head in charge of Marketing Division June 2025 Managing Executive Officer; Division Manager, In-Hospital Testing Division; Department Manager, Second In-Hospital Testing Department; and Deputy Head in charge of Marketing Division; Deputy Head in charge of BML Testing Division To present </p> <p data-bbox="432 1043 1283 1312"> (Reasons for nomination) Since joining the Company, Mr. Masami Kondo has experienced operations at laboratories and branches in the testing division, as well as operations in the marketing division. In the both divisions, he has abundant experience as an executive manager. He also has deep insights in the overall business of the Company. By utilizing such achievements, expertise as well as insights on strategy planning, the Company has judged that he is personnel necessary to increase the future corporate value of the Group, and therefore nominates him as a candidate for Director. </p>	8,076

No.	Name (Date of birth)	Past experience, positions and responsibilities in the Company	Number of shares of the Company held
7	 <p>Shigeru Osawa (May 13, 1957)</p> <p>(Reappointment) (Outside) (Independent)</p>	<p>April 1980 Joined The Kyowa Bank, Ltd. (currently Resona Bank, Limited)</p> <p>April 2002 Tsubasa Systems Co., Ltd.</p> <p>June 2006 Managing Officer, Yahagi Construction Co., Ltd.</p> <p>June 2007 Director and Senior Managing Officer</p> <p>June 2010 Representative Director and Senior Managing Officer</p> <p>April 2012 Vice President and Representative Director</p> <p>June 2021 Advisor</p> <p>June 2022 Outside Director of the Company</p> <p>To present</p> <p>(Reasons for nomination as a candidate for Outside Director and summary of expected roles)</p> <p>Mr. Shigeru Osawa has abundant experience and deep insights in the financial and construction fields. By utilizing such achievements, expertise as well as insights on management, the Company judged that he is personnel necessary to increase future corporate value of the Group through giving opinions and making judgements from an objective standpoint when making decisions for the management of the Company, and through playing a role of monitoring and supervising Directors' execution of duties, and therefore nominates him again as a candidate for Outside Director. The Company expects him to fulfill his role of supervising the management from a position independent from executive officers by utilizing his wealth of experience to date.</p> <p>It has been four years since the appointment of Mr. Shigeru Osawa as Outside Director of the Company as of the conclusion of this Annual General Meeting of Shareholders.</p>	836

No.	Name (Date of birth)	Past experience, positions and responsibilities in the Company	Number of shares of the Company held
8	 <p data-bbox="188 846 400 907">Reiko Matsuzawa (September 5, 1963)</p> <p data-bbox="188 936 400 1025">(Reappointment) (Outside) (Independent)</p>	<p data-bbox="421 271 1294 353">April 1982 Joined the National Tax Agency. Co-ordination Division of the Management and Co-ordination Department, Osaka Regional Taxation Bureau</p> <p data-bbox="421 360 1294 421">July 2013 Deputy District Director, Kawasaki-Minami Tax Office, Tokyo Regional Taxation Bureau</p> <p data-bbox="421 427 1294 488">July 2015 Commissioner's Secretariat and Internal Inspector, National Tax Agency</p> <p data-bbox="421 495 1294 555">July 2017 Special Examiner, First Large Enterprise Examination Department, Tokyo Regional Taxation Bureau</p> <p data-bbox="421 562 1294 622">July 2018 District Director, Abeno Municipal Tax Office, Osaka Regional Taxation Bureau</p> <p data-bbox="421 629 1294 689">July 2019 Chief Examiner, Forty-first Large Enterprise Examination Group, Fourth Large Enterprise Examination Department</p> <p data-bbox="421 696 1294 757">July 2020 Director, Co-ordination Division, Third Large Enterprise Department, Tokyo Regional Taxation Bureau</p> <p data-bbox="421 763 1294 824">July 2021 Commissioner's Secretariat and Director (Health and Welfare), National Tax Agency</p> <p data-bbox="421 831 1294 891">July 2022 Assistant Regional Commissioner (Planning and Administration), Kumamoto Regional Taxation Bureau</p> <p data-bbox="421 898 1294 958">July 2023 Regional Commissioner, Okinawa Regional Taxation Office and Director of Okinawa Training Center, National Tax College</p> <p data-bbox="421 965 1294 994">September 2024 Director, Reiko Matsuzawa Tax Accountant Office</p> <p data-bbox="421 1001 1294 1030">June 2025 Outside Director of the Company</p> <p data-bbox="421 1037 1294 1066">To present</p> <p data-bbox="421 1072 1294 1102">[Significant concurrent positions]</p> <ul data-bbox="421 1108 1294 1160" style="list-style-type: none"> • Outside Director (Audit and Supervisory Board Member), Yamatane Corporation • Auditor, The Kikuyou Bunka Kyokai (to be assumed in June 2026) <p data-bbox="421 1167 1294 1196">(Reasons for nomination as a candidate for Outside Director and summary of expected roles)</p> <p data-bbox="421 1202 1294 1391">Ms. Reiko Matsuzawa has expert knowledge and deep insights as a tax accountant. By utilizing such achievements and expert insights, the Company judged that she is personnel necessary to increase future corporate value of the Group through giving opinions and making judgements from an objective standpoint when making decisions for the management of the Company, and through playing a role of monitoring and supervising Directors' execution of duties, and therefore nominates her again as a candidate for Outside Director.</p> <p data-bbox="421 1397 1294 1538">The Company expects her to fulfill her role of supervising the management from a position independent from executive officers by utilizing her wealth of experience to date. It has been one year since the appointment of Ms. Reiko Matsuzawa as Outside Director of the Company as of the conclusion of this Annual General Meeting of Shareholders.</p>	356

No.	Name (Date of birth)	Past experience, positions and responsibilities in the Company	Number of shares of the Company held
9	 <p>Toyohiko Kagawa (April 9, 1957)</p> <p>(New appointment) (Outside) (Independent)</p>	<p>April 1981 Joined The Japan Steel Works, Ltd. December 2002 General Manager, Planning Management Department, Ordnance Headquarters July 2008 General Manager, Ordnance Management Department, Hiroshima Plant April 2010 Deputy Plant Manager, Hiroshima Plant April 2014 General Manager, Ordnance Sales Department, Head Office April 2016 Executive Officer, Director of Ordnance Headquarters, Head Office October 2019 Managing Executive Officer, Director of Ordnance Headquarters, Head Office April 2022 Adviser, NIKKO TOKKI CO.,LTD. June 2022 Representative Director & President June 2025 Executive Adviser To present</p> <p>[Significant concurrent positions] Executive Adviser, NIKKO TOKKI CO., LTD. (Reasons for nomination as a candidate for Outside Director and summary of expected roles) Mr. Toyohiko Kagawa has abundant experience and deep insights, as being in charge of products for Ministry of Defense at a general machinery manufacturing group centering on various industrial machineries. By utilizing such achievements, expertise as well as insights on management, the Company judged that he is personnel necessary to increase future corporate value of the Group through giving opinions and making judgements from an objective standpoint when making decisions for the management of the Company, and through playing a role of monitoring and supervising Directors' execution of duties, and therefore nominates him as a candidate for Outside Director. The Company expects him to fulfill his role of supervising the management from a position independent from executive officers by utilizing his wealth of experience to date.</p>	0

(Notes)

1. There are no special interests between the candidates for Directors and the Company.
2. Ms. Reiko Matsuzawa's attendance at meetings of the Board of Directors reflects the meetings held after her assumption of office as Director.
3. Mr. Shigeru Osawa, Ms. Reiko Matsuzawa, and Mr. Toyohiko Kagawa are candidates for Outside Directors.
4. The Company has registered Mr. Shigeru Osawa and Ms. Reiko Matsuzawa as Independent Directors with the Tokyo Stock Exchange.
5. If Mr. Toyohiko Kagawa is elected as proposed, the Company will register him as an Independent Director with the Tokyo Stock Exchange.
6. The Company has entered into agreements with Mr. Shigeru Osawa and Ms. Reiko Matsuzawa in accordance with Article 427, Paragraph 1 of the Companies Act to limit their liability for damages under Article 423, Paragraph 1 of the same act. The maximum amount of liability for damages pursuant to the agreement is the minimum amount stipulated by laws and regulations. If they are reelected and assume office as Outside Directors of the Company, the agreement shall continue to be effective.
7. If Mr. Toyohiko Kagawa is elected as proposed, the Company intends to enter into an agreement with him in accordance with Article 427, Paragraph 1 of the Companies Act to limit his liability for damages under Article 423, Paragraph 1 of the same act. The maximum amount of liability for damages pursuant to the agreement will be the minimum amount stipulated by laws and regulations.
8. The Company has concluded with an insurance company a directors and officers liability insurance contract as stipulated in Article 430-3, Paragraph 1 of the Companies Act. This contract covers damages that may arise due to the insured being liable for performance of duties or receiving a claim related to the pursuit of such liability. However, the contract includes certain exclusions, such as no coverage for liability resulting from actions taken with the knowledge that they violate laws and regulations. The Company bears all of the insurance premium for the directors and officers liability insurance contract. Each candidate will be insured under the said insurance contract. The directors and officers liability insurance contracts shall be renewed on March 1, 2027, in the middle of each candidate's term of office.
9. The number of shares of the Company held by each candidate for Director refers to the actual number of shares held by each of them including the shares under the BML Group officers' shareholding association.

Proposal 3: Election of 1 Substitute Director Who Is an Audit and Supervisory Committee Member

To prepare for cases where a vacancy results in a shortfall in the number of Directors who are Audit and Supervisory Committee Members prescribed by laws and regulations, the Company proposes the election of one Substitute Director who is an Audit and Supervisory Committee Member.

The Audit and Supervisory Committee has given its approval to this proposal.

The candidate for Substitute Director who is an Audit and Supervisory Committee Member is as follows:

Name (Date of birth)	Past experience, positions and responsibilities in the Company	Number of shares of the Company held
<p>Shunsuke Nohara (November 11, 1979)</p> <p>(Outside) (Independent)</p>	<p>October 2006 Registered as attorney at law (Dai-ichi Tokyo Bar Association) Joined KOHWA SOHGOH LAW OFFICES</p> <p>August 2015 Joined Kelvin Chia Partnership</p> <p>January 2016 Admitted as attorney at law in New York, USA</p> <p>October 2016 Senior Partner, KOHWA SOHGOH LAW OFFICES (incumbent)</p> <p>August 2022 Outside Corporate Auditor, Cocolive Inc. (incumbent)</p> <p>October 2023 Outside Corporate Auditor, Olive Union Inc. To present</p> <p>(Reasons for nomination as a candidate for Substitute Outside Director who is an Audit and Supervisory Committee Member and summary of expected roles) The Company proposes that Mr. Shunsuke Nohara be elected as Substitute Director who is an Audit and Supervisory Committee Member since we judged that his expertise as an attorney at law and abundant experience as a corporate lawyer can be used for enhancing the audit structure of the Company, even though he has never been involved in corporate management.</p>	<p>0</p>

(Notes)

1. Mr. Shunsuke Nohara is a candidate for Substitute Outside Director who is an Audit and Supervisory Committee Member.
2. The Company has not entered into an advisory contract with the candidate.
3. If Mr. Shunsuke Nohara assumes office as an Outside Director who is an Audit and Supervisory Committee Member, the Company plans to enter into an agreement with him in accordance with Article 427, Paragraph 1 of the Companies Act to limit his liability for damages pursuant to Article 423, Paragraph 1 of the same act. The maximum amount of liability for damages pursuant to the agreement is the minimum amount stipulated by laws and regulations.
4. The Company has concluded with an insurance company a directors and officers liability insurance contract as stipulated in Article 430-3, Paragraph 1 of the Companies Act. This contract covers damages that may arise due to the insured being liable for performance of duties or receiving a claim related to the pursuit of such liability. However, the contract includes certain exclusions, such as no coverage for liability resulting from actions taken with the knowledge that they violate laws and regulations. The Company bears all of the insurance premium for the directors and officers liability insurance contract. If the candidate assumes office as Outside Director who is an Audit and Supervisory Committee Member, he will be insured under the said insurance contract.
5. Mr. Shunsuke Nohara satisfies the requirement as Independent Director prescribed by the Tokyo Stock Exchange. If he assumes office as Outside Director who is an Audit and Supervisory Committee Member, the Company will register him as an Independent Director with the Tokyo Stock Exchange.

(Reference) Composition of the Board (after this General Meeting of Shareholders)

Directors:

Name	Positions in the Company	Areas which the Company specifically expect candidates for Directors to cover							
		Management Experience	Medical Experience	Inspection/ Engineering	Information Technology	Strategy Planning	Finance/ Accounting	Personnel/ Labor	Risk/Legal Affairs
Kensuke Kondo	President and Representative Director	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>		<input type="radio"/>			<input type="radio"/>
Norihisa Takebe	Representative Director; Senior Managing Executive Officer	<input type="radio"/>				<input type="radio"/>	<input type="radio"/>		<input type="radio"/>
Kenji Shibata	Director; Managing Executive Officer			<input type="radio"/>		<input type="radio"/>			
Masami Kondo	Director; Managing Executive Officer			<input type="radio"/>		<input type="radio"/>			
Hideaki Osawa	Director; Executive Officer					<input type="radio"/>			
Yuji Yamashita	Director; Executive Officer			<input type="radio"/>	<input type="radio"/>	<input type="radio"/>			
Shigeru Osawa	Outside Director	<input type="radio"/>		<input type="radio"/>		<input type="radio"/>	<input type="radio"/>		
Reiko Matsuzawa	Outside Director						<input type="radio"/>	<input type="radio"/>	
Toyohiko Kagawa	Outside Director	<input type="radio"/>		<input type="radio"/>		<input type="radio"/>			
Kenichi Morishita	Director (Full-Time Audit and Supervisory Committee Member)						<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Masato Denawa	Outside Director (Audit and Supervisory Committee Member)							<input type="radio"/>	<input type="radio"/>
Noriko Miyagi	Outside Director (Audit and Supervisory Committee Member)						<input type="radio"/>	<input type="radio"/>	

The above list does not present all of the knowledge and experience possessed by the candidates.